MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 412145 | Name: BN 50726

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BN 50726 is a platelet activating factor inhibitor; antagonizes PAF receptor binding.

Chemical Structure

BN 50726
CAS#127279-06-5

Theoretical Analysis

MedKoo Cat#: 412145

Name: BN 50726

CAS#: 127279-06-5

Chemical Formula: C34H48ClN5O2S2

Exact Mass: 657.2938

Molecular Weight: 658.36

Elemental Analysis: C, 62.03; H, 7.35; Cl, 5.38; N, 10.64; O, 4.86; S, 9.74

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
BN 50726; BN-50726; BN50726
IUPAC/Chemical Name
BN 50726
InChi Key
XYNVFDKKFDLTPP-UHFFFAOYSA-N
InChi Code
InChI=1S/C34H48ClN5O2S2/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-18-23-44(41,42)39-22-21-28-30(25-39)43-34-32(28)33(27-19-16-17-20-29(27)35)36-24-31-38-37-26(2)40(31)34/h16-17,19-20H,3-15,18,21-25H2,1-2H3
SMILES Code
CCCCCCCCCCCCCCCCS(=O)(N1CCc2c(C(c3c(Cl)cccc3)=NCc4n5c(C)nn4)c5sc2C1)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 658.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Negro Alvarez JM, Miralles López JC, Ortiz Martínez JL, Abellán Alemán A, Rubio del Barrio R. Platelet-activating factor antagonists. Allergol Immunopathol (Madr). 1997 Sep-Oct;25(5):249-58. PMID: 9395010. 2: Nguyên P, Petitfrère E, Potron G. Mechanisms of the platelet aggregation induced by activated neutrophils and inhibitory effect of specific PAF receptor antagonists. Thromb Res. 1995 Apr 1;78(1):33-42. doi: 10.1016/0049-3848(95)00032-1. PMID: 7778064. 3: Massicot F, Warnet JM, Dutertre-Catella H, Martin C, Braquet P, Claude JR. Protection against cyclosporin-induced nephrotoxicity: 1. Effect of a PAF antagonist, BN50726. J Lipid Mediat Cell Signal. 1994 May;9(3):217-24. PMID: 7921781. 4: Steen VM, Holmsen H, Aarbakke G. The platelet-stimulating effect of adrenaline through alpha 2-adrenergic receptors requires simultaneous activation by a true stimulatory platelet agonist. Evidence that adrenaline per se does not induce human platelet activation in vitro. Thromb Haemost. 1993 Sep 1;70(3):506-13. PMID: 8259557. 5: Chakrabarty S, Fluck DS, Flores NA, Sheridan DJ. Effects of the PAF antagonists BN50726 and BN50739 on arrhythmogenesis and extent of necrosis during myocardial ischaemia/reperfusion in rabbits. Br J Pharmacol. 1992 Nov;107(3):705-9. doi: 10.1111/j.1476-5381.1992.tb14510.x. PMID: 1472967; PMCID: PMC1907739. 6: Zarco P, Maestre C, Herrero-Beaumont G, González E, Garcia-Hoyo R, Navarro FJ, Braquet P, Egido J. Involvement of platelet-activating factor and tumour necrosis factor in the pathogenesis of joint inflammation in rabbits. Clin Exp Immunol. 1992 May;88(2):318-23. doi: 10.1111/j.1365-2249.1992.tb03080.x. PMID: 1315229; PMCID: PMC1554314. 7: Bazan HE, Reddy ST, Lin N. Platelet-activating factor (PAF) accumulation correlates with injury in the cornea. Exp Eye Res. 1991 Apr;52(4):481-91. doi: 10.1016/0014-4835(91)90046-h. PMID: 2037028. 8: Braquet P, Esanu A. New trends in PAF antagonist research: a new series of potent hetrapazine-derived PAF antagonists. Agents Actions. 1991 Jan;32(1-2):34-6. doi: 10.1007/BF01983304. PMID: 2058466. 9: Gilboe DD, Kintner D, Fitzpatrick JH, Emoto SE, Esanu A, Braquet PG, Bazan NG. Recovery of postischemic brain metabolism and function following treatment with a free radical scavenger and platelet-activating factor antagonists. J Neurochem. 1991 Jan;56(1):311-9. doi: 10.1111/j.1471-4159.1991.tb02597.x. PMID: 1987322. 10: Braquet P, Laurent JP, Rolland A, Martin C, Pommier J, Hosford D, Esanu A. From ginkgolides to N-substituted piperidino-thieno diazepines, a new series of highly potent dual antagonists. Adv Prostaglandin Thromboxane Leukot Res. 1991;21B:929-37. PMID: 1825436. 11: Yue TL, Rabinovici R, Farhat M, Feuerstein G. Inhibitory effect of new PAF antagonists on PAF-induced rabbit platelet aggregation in vitro and ex vivo. J Lipid Mediat. 1991 Jan-Feb;3(1):13-26. PMID: 1768837. 12: Lin N, Bazan HE, Braquet P, Bazan NG. Prolonged effect of a new platelet- activating factor antagonist on ocular vascular permeability in an endotoxin model of uveitis. Curr Eye Res. 1991 Jan;10(1):19-24. doi: 10.3109/02713689109007607. PMID: 1709399. 13: Yue TL, Rabinovici R, Farhat M, Feuerstein G. Pharmacologic profile of BN 50739, a new PAF antagonist in vitro and in vivo. Prostaglandins. 1990 May;39(5):469-80. doi: 10.1016/0090-6980(90)90031-p. PMID: 2353116. 14: Pignol B, Lonchampt MO, Chabrier PE, Mencia-Huerta JM, Braquet P. Platelet- activating factor potentiates interleukin-1/epidermal cell-derived thymocyte- activating factor release by guinea-pig keratinocytes stimulated with lipopolysaccharide. J Lipid Mediat. 1990;2 Suppl:S83-91. PMID: 2133287. 15: Pletscher A, Ferracin F, Gurari-Rotman D. LDL induced shape change reaction of platelets is not due to PAF. Thromb Res. 1989 Nov 15;56(4):571-2. doi: 10.1016/0049-3848(89)90243-0. PMID: 2609294. 16: Howat DW, Chand N, Braquet P, Willoughby DA. An investigation into the possible involvement of platelet activating factor in experimental allergic encephalomyelitis in rats. Agents Actions. 1989 Jun;27(3-4):473-6. doi: 10.1007/BF01972856. PMID: 2801340.